en · de · es · pt
glossary-desk.peptides6908.com › News › Background And Receptor Mechanism — Deep Dive

Background And Receptor Mechanism — Deep Dive

By Editorial Desk · published 2025-10-18 · last reviewed 2025-12-10 · News

Everything below concerns analytical characterisation. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Last reviewed on 2025-12-10. Where a claim depends on a specific study, the study is described rather than over-claimed.

Background and Receptor Mechanism

Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.

Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.

Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.

Analytical Methods And Storage Stability

Verification of a purchased sample requires documentation linking a batch to a certificate of analysis, and that document should be read for the methods used rather than the headline purity figure. A single chromatographic percentage does not establish identity. Independent laboratories can perform identity and content assays, but no such test establishes that a product is suitable for human use. Claims about efficacy rest largely on small, early studies rather than on replicated controlled trials, and that gap remains open.

Identity testing for a cyclic peptide of this size usually relies on reversed-phase high-performance liquid chromatography coupled to mass spectrometry. The mass spectrum confirms molecular weight, while the chromatographic trace indicates the proportion of related impurities. Tandem mass spectrometry can provide sequence-level information when fragmentation data are compared against a reference standard. Nuclear magnetic resonance is sometimes used to confirm the lactam bridge, although it requires more material and greater operator expertise than routine chromatographic methods.

Lyophilised peptide powder is comparatively stable when kept dry, cold and protected from light. Once dissolved, the molecule is exposed to hydrolysis, oxidation and microbial growth, and degradation accelerates at higher temperatures and in alkaline solution. Repeated freeze-thaw cycles concentrate solutes and promote aggregation. Handling guidance for research peptides commonly clusters around freezer temperatures for powder and short refrigerated use for reconstituted solutions, with pH control and sterile technique applied throughout.

Melanotan-2 at a glance

PropertyValueNotes
Chemical classSynthetic cyclic heptapeptideAnalog of alpha-melanocyte-stimulating hormone
Primary receptor familyMelanocortin receptors MC1R through MC5RBinding is not subtype-selective
Development period1980sSynthesized during pigmentation and appetite research
Regulatory statusNot an approved medicineNo major regulator has authorized human use
Related compoundAfamelanotideLinear analog studied for photoprotection

Origins and Research Status

The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.

Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.

Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.

Related pages on this site

Handling, Storage, and Analytical Verification

Lyophilised melanotan-2 is supplied as a solid, which is more stable than a solution. The material is hygroscopic, so weighing is done quickly, in low humidity, with the container kept sealed. Reconstitution usually uses water for injection or bacteriostatic water, added down the wall of the vial to limit foaming. A reconstituted solution is held at 2 to 8 °C and kept away from light. Repeated freezing and thawing of the same vial is avoided because ice crystal formation and concentration effects degrade the peptide.

Reversed-phase high-performance liquid chromatography is the routine method for purity assessment. Peptides absorb near 214 nm because of the peptide bond, and a gradient of acetonitrile in water separates the intact peptide from deletion sequences, oxidised products, and earlier-eluting fragments at neutral pH. Electrospray ionisation mass spectrometry provides an orthogonal check: the measured mass must agree with the theoretical value. Amino acid analysis and peptide mapping confirm structure but are used less often. Reference standards remain scarce because the peptide is not described in any pharmacopoeia.

Background and Chemical Profile

Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.

Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.

The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.

Regulatory Status and Literature Discussion

Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.

Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.

Further detail

The various temperature rests favour the activity of different enzymes, depending on the type and modification level of the malt and the brewer's intentions. Of particular importance are α-amylase and β-amylase, which hydrolyse starch to produce dextrins and fermentable sugars such as maltose. A traditional step mash may include a β-glucanase and protein rest around 45 °C (113 °F), a β-amylase rest around 62 °C (144 °F), and an α-amylase rest around 70 °C (158 °F). With modern well-modified malts, the lower-temperature rests are often omitted, and mashing may begin directly at temperatures where the amylases are more active. β-glucanases break down β-glucans in the mash, while proteolytic enzymes break down proteins into smaller peptides and amino acids. In modern brewing, commercial β-glucanase preparations may also be added to the mash. During saccharification, a mash rest of around 65–71 °C (149–160 °F) is commonly used. Lower temperatures within this range favour β-amylase activity and generally produce a more fermentable wort, while higher temperatures favour α-amylase activity and generally produce a less fermentable wort containing more dextrins. Mash temperature, duration and pH therefore influence the carbohydrate composition and fermentability of the resulting wort.

=== Environmental practices === In 1999, Starbucks started the "Grounds for your Garden" program. This gives leftover coffee grounds to anyone requesting it for composting. The goal of the program was to make the company environmentally friendlier. Although not all stores and regions participate, customers can request and lobby their local store to begin the practice. In October 2008, The Guardian newspaper reported that Starbucks was wasting 6.2 million U.S. gallons (23.4 million liters) of water a day by leaving a tap constantly running for rinsing utensils in a 'dipper well' in each of its stores, but this is often required by governmental food safety codes. In June 2009, in response to concerns over its excessive water consumption, Starbucks re-evaluated its use of the dipper well system. In September 2009, company-operated Starbucks stores in Canada and the United States successfully implemented a new water saving solution that meets government health standards. Different types of milk are given a dedicated spoon that remains in the pitcher and the dipper wells were replaced with push button metered faucets for rinsing. This would reportedly save up to 150 U.S. gallons (570 liters) of water per day in every store. In January 2020, Starbucks shared its new environmental sustainability commitment to become a resource positive company. It announced three preliminary targets: By 2030, Starbucks will aim to reduce its carbon emissions, waste output, and water impact by 50%.

The receptors for the RLN/INSL peptides are collectively called "Relaxin family peptide receptors (RXFPs)". In humans there are four RXFP receptors (RXFP1-4) all of which are cell membrane-associated and coupled to G-proteins (known as G protein-coupled receptors or GPCRs). There are two distinct families of RXFPs: RXFP1 and RXFP2 are evolutionarily related to the receptors of follicle-stimulating hormone (FSH) and LH, and are the cognate receptors for RLN and INSL3 respectively in humans. On the other hand, RXFP3 and RXFP4 are related to somatostatin and, in humans, are the cognate receptors for RLN3 and INSL5. There is evidence that some relaxin hormones may also be able to interact with glucocorticoid-type nuclear receptors, which float freely between the cytoplasm and nucleoplasm.

== Side effects == The US prescription label contains a boxed warning for hypotension and syncope in certain settings. The majority of adverse events are mild to moderate in severity. The most commonly reported adverse events included dizziness, nausea, feeling tired, sleepiness, and trouble sleeping. Drinking alcohol while on flibanserin may increase the risk of severe low blood pressure.

=== 1982 === February 24: President Ronald Reagan announces the "Caribbean Basin Initiative" to prevent the overthrow of governments in the region by the forces of communism. March 22: President Ronald Reagan signs P.L. 97-157 denouncing the government of the Soviet Union that it should cease its abuses of the basic human rights of its citizens. April 2: Argentina invades the Falkland Islands, starting the Falklands War. May 30: Spain joins NATO. June 6: Israel invades Lebanon to end raids and clashes with Syrian troops based there. June 14: Falkland Islands liberated by British task force. End of the Falklands War. August 1: Rebels attempt to seize control of Kenya, with the supposed assist of the communists in a coup d'état. The coup failed. November 10: Leonid Brezhnev dies from a heart failure with his funeral being held five days later. November 14: Yuri Andropov becomes General Secretary of the Soviet Union.

Sources: en.wikipedia.org

Supporting material

Before the ghetto riot of 1967, Detroit's black population had the highest rate of home-ownership of any black urban population in the country, and their unemployment rate was just 3.4 percent. It was not despairing that fueled the riot. It was the riot which marked the beginning of the decline of Detroit to its current state of despair. Detroit's population today is only half of what it once was, and its most productive people have been the ones who fled. However, Thomas Sugrue argues that over 20% of Detroit's adult black population was out of work in the 1950s and 1960s, along with 30% of black youth between eighteen and twenty-four. Economist Edward L. Glaeser believes the riots were a symptom of the city's already downward trajectory:

=== Similar diseases with overlapping symptoms === Bullous Pemphigoid, Cicatricial Pemphigoid, Drug Eruptions. Epidermolysis Bullosa, Epidermolysis Bullosa Acquisita, Erythema Multiforme, Lichen Planus, pemphigus vulgaris, Stevens–Johnson syndrome and toxic epidermal necrolysis. PNP is most commonly mistaken for pemphigus vulgaris, due to the extreme similarities of the lesions that develop. However, the difference lies in the specificity of the autoreactive antibodies in each case.

== History == Hohhot Baita Airport was opened on 1 October 1958. When it first opened to air traffic, it had only one dirt runway, three single‑story buildings, and five tents. The taxiway and apron were simple, and the runway measured 1,500 meters in length and 100 meters in width. In the mid-1980s and 1990s, it underwent two expansions and in June 2007 a new terminal was constructed. The new terminal covers an area of 54,499 square metres (586,620 sq ft) with 11 parking jetways and is capable of handling three million passengers each year. Its runway was also lengthened and its widened to accommodate jumbo jets such as the Airbus A380. It served as one of the diversion airports for air traffic during the 2008 Summer Olympics. With the rapid expansion of the city, Baita Airport is now surrounded by urban area and has no more room to expand to accommodate growing traffic. The Hohhot Shengle International Airport is being constructed in Horinger County which will replace Baita Airport and Baita is set to be closed once the new airport opened.

== Mechanical properties == To ensure durability of PCs, mechanical properties are important to study. Elaborate efforts have been made for studying compressive brittleness of porous carbon materials. In 1999, Iizuka, et al. studied the mechanical properties of wood ceramics, a type of porous carbon material. Stable medium-density fiber was used as the base material of wood ceramics and phenol resin was impregnated into the board. Starting at 300 °C, Young's modulus and the compressive strength first decreased with increasing temperature, but at 500 °C the strength increases sharply until it reaches 800 °C and plateaus. The effects of temperature were due to microstructural changes in the resin during carbonization. Effects of impregnates phenol resin at 800 °C were also investigated. Results showed that Young's modulus increased with phenol resin impregnation (Figure 1). The maximum Young's modulus was 5 MPa and the maximum compressive strength was 80 MPa. Wall-bending mechanical test were also performed and it was found that cell wall is breakage was correlated to relative density on compressive strength and Young's modulus. Another type of compressive porous carbon consisting of cellulose and graphene aerogels was studied by Mi, et al. Modified cellulose/graphene aerogels (MCGA) was synthesized via bidirectional freeze drying and grafting of long carbon chains through chemical vapor deposition (Figure 2). The final product had a bulk density of 5.9 mg/cm3 and surface area of 47.3 m2/g with flexible cellulose nanofibril and stiff graphene components.

Sources: en.wikipedia.org

Frequently asked questions

Is melanotan II an approved medication?

No regulator in a major market has approved it for human use. It appears in research settings and in products marketed outside pharmacy channels. Legal status for personal possession varies by country.

How does it differ from afamelanotide?

Afamelanotide is a linear analog that has received approval in some jurisdictions for a specific photoprotection indication. Melanotan II is cyclic and less selective across melanocortin receptors. The two are related but are not interchangeable in regulatory or clinical terms.

Why does receptor selectivity matter?

A compound that activates several receptor subtypes may produce effects beyond pigmentation. Selectivity influences which tissues respond and shapes the side-effect profile described in reports. Designing subtype-selective analogs is a stated goal of melanocortin research.

Which analytical technique is most informative for identity?

Mass spectrometry combined with liquid chromatography provides both molecular weight confirmation and a measure of related impurities. Tandem mass spectrometry adds sequence information. A purity percentage reported without a mass measurement does not confirm what the material is.

Network